清燥救肺汤加味治疗气阴两虚证哮喘-慢性阻塞性肺疾病重叠综合征的疗效观察
|
摘要
目的:研究清燥救肺汤加味治疗气阴两虚证哮喘-慢性阻塞性肺疾病重叠综合征的疗效观察。方法:选择2016年10月—2017年10月期间在本院接受诊治的118例气阴两虚证哮喘-COPD重叠综合征患者作为观察对象,参照随机数表法分成对照组、研究组,各59例。对照组患者采用盐酸氨溴索联合信必可都保吸入剂治疗,研究组患者采用清燥救肺汤加味治疗,持续治疗1个月。对比两组患者治疗效果及治疗前后血清炎症因子、肺功能变化。结果:研究组患者的治疗总有效率94. 9%(56/59)高于对照组的83. 1%(49/59),差异有统计学意义(P <0. 05);治疗前,两组患者的血清炎症因子(IL-10、TNF-α)指标差异无统计学意义(P> 0. 05);两组治疗后的血清炎症因子IL-10、TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P <0. 05);治疗前,两组患者的肺功能(FEV1、FVC、FEV1/FVC)指标差异无统计学意义(P> 0. 05);两组治疗后的肺功能指标FEV1、FVC、FEV1/FVC水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P <0. 05)。结论:清燥救肺汤加味治疗气阴两虚证哮喘-慢性阻塞性肺疾病重叠综合征效果显著,能有效缓解或消除临床症状,减轻机体炎症反应,提高患者肺功能。
Objective: To study the effect of Qingzao Jiufei Decoction in the treatment of both deficiency of Qi and Yin type of asthma-chronic obstructive pulmonary disease overlapping syndrome. Methods: Totally 118 cases of patients with asthma and COPD overlap syndrome who were diagnosed and treated in our hospital from October 2016 to October 2017 were selected as subjects. All the patients were divided into the control group and the study group according to the random number table method,59 cases in each group. The patients in the control group were treated with ambroxol hydrochloride and Budesonide and Formoterol Fumarate Powder for Inhalation. And the patients in the study group were treated with Qingzao Jiufei Decoction,lasting for one month. The treatment effects and the changes of serum inflammatory factors and lung function before and after treatment were compared between the two groups. Results: The total effective rate of treatment in the study group was 94. 9%( 56/59) which was higher than that in the control group( 83. 1%)( 49/59) and the difference was statistically significant( P < 0. 05). Before treatment,there was no significant difference in serum inflammatory factors( IL-10,TNF-α) between the two groups( P > 0. 05).The levels of serum inflammatory cytokines IL-10 and TNF-α after treatment in the two groups were lower than those before treatment,and the study group's were lower than those of the control group,and the difference was statistically significant( P <0. 05). Before treatment,there was no significant difference in lung function( FEV1,FVC,FEV1/FVC) indexes between the two groups( P > 0. 05). The levels of FEV1,FVC and FEV1/FVC in the two groups after treatment were higher than those before treatment. The study group's were higher than those of the control group and the difference was statistically significant( P <0. 05). Conclusion: Qingzao Jiufei Decoction for the treatment of both deficiency of Qi and Yin type of asthma-chronic obstructive pulmonary disease overlapping syndrome has a significant effect and can effectively relieve or eliminate clinical symptoms,reduce inflammation and improve lung function.
Objective: To study the effect of Qingzao Jiufei Decoction in the treatment of both deficiency of Qi and Yin type of asthma-chronic obstructive pulmonary disease overlapping syndrome. Methods: Totally 118 cases of patients with asthma and COPD overlap syndrome who were diagnosed and treated in our hospital from October 2016 to October 2017 were selected as subjects. All the patients were divided into the control group and the study group according to the random number table method,59 cases in each group. The patients in the control group were treated with ambroxol hydrochloride and Budesonide and Formoterol Fumarate Powder for Inhalation. And the patients in the study group were treated with Qingzao Jiufei Decoction,lasting for one month. The treatment effects and the changes of serum inflammatory factors and lung function before and after treatment were compared between the two groups. Results: The total effective rate of treatment in the study group was 94. 9%( 56/59) which was higher than that in the control group( 83. 1%)( 49/59) and the difference was statistically significant( P < 0. 05). Before treatment,there was no significant difference in serum inflammatory factors( IL-10,TNF-α) between the two groups( P > 0. 05).The levels of serum inflammatory cytokines IL-10 and TNF-α after treatment in the two groups were lower than those before treatment,and the study group's were lower than those of the control group,and the difference was statistically significant( P <0. 05). Before treatment,there was no significant difference in lung function( FEV1,FVC,FEV1/FVC) indexes between the two groups( P > 0. 05). The levels of FEV1,FVC and FEV1/FVC in the two groups after treatment were higher than those before treatment. The study group's were higher than those of the control group and the difference was statistically significant( P <0. 05). Conclusion: Qingzao Jiufei Decoction for the treatment of both deficiency of Qi and Yin type of asthma-chronic obstructive pulmonary disease overlapping syndrome has a significant effect and can effectively relieve or eliminate clinical symptoms,reduce inflammation and improve lung function.
引文
[1]汪颖,王迪芬,刘颖,等. AECOPD与ARDS患者动脉血气特点及短期疗效比较[J].贵州医科大学学报,2017,42(8):919-923.
[2]Mao T,Chen H,Hong L,et al. Pigment epithelium-derived factor inhibits high glucose-induced JAK/STAT signalling pathway activation in human glomerular mesangial cells[J]. Saudi Medical Journal,2013,12(34):3213-3215.
[3]李慧丽,焦凤梅,田昭涛,等.氧驱雾化吸入盐酸氨溴索治疗COPD急性加重期患者的临床疗效观察[J].湖南师范大学学报:医学版,2016,13(3):133-135.
[4]林金鱼,陈亚红.不同剂量盐酸氨溴索治疗慢性阻塞性肺疾病急性加重期老年患者的疗效比较[J].中国医药,2014,9(8):1120-1124.
[5]高静珍,陈宝元.盐酸氨溴索不同持续使用时间对慢性阻塞性肺疾病急性加重期的治疗效果[J].中华老年医学杂志,2014,33(3):294-296.
[6]陈锦平.盐酸氨溴索对慢性阻塞性肺疾病急性加重期肺功能及血清IL-10、TNF-α、CRP的影响[J].广西医学,2014,36(7):964-965,974.
[7]许斐,刘彦辉,刘晓芳.左西孟旦联合西地那非治疗慢性心力衰竭伴肺动脉高压的疗效观察[J].中西医结合心血管病电子杂志,2015,3(12):27,29.
[8]杨菊芳.分析麻杏石甘汤与银翘散联合加减治疗支气管肺炎患儿的临床疗效及安全性[J].中外医疗,2017,36(26):154-155,158.
[9]郭晓燕,徐向前,钱家骅,等.川芎平喘合剂对慢性阻塞性肺疾病肺动脉高压大鼠肺动脉平滑肌细胞增殖及对Rho激酶的影响[J].辽宁中医杂志,2017,44(12):2662-2664.
[10]董胜莲,汪凤兰,邢凤梅,等.自我效能系统干预对慢性阻塞性肺疾病患者生存质量的影响[J].现代预防医学,2014,41(18):3357-3359.
[11]郑灵春.布地奈德联合盐酸氨溴索雾化吸入治疗COPD急性加重期患者的疗效观察[J].医药前沿,2017,7(23):44-45.
[12]张丹凤,罗彩凤.赋能呼吸康复训练对慢性阻塞性肺疾病患者自我效能的影响[J].广东医学,2014,35(24):3932-3933.
[13]曹利花.舒适护理对老年慢性阻塞性肺疾病患者临床症状治疗依从性及生活自理能力的影响[J].中国药物与临床,2017,17(5):770-772.
[14]徐洪建.盐酸氨溴索联合α-糜蛋白酶雾化吸入治疗COPD急性加重期患者的疗效[J].中国处方药,2016,14(5):59-60.
[15]冼少静,石湘淋,黄奕江.慢性阻塞性肺疾病伴呼吸衰竭患者两种通气模式应用比较研究[J].湖南师范大学学报:医学版,2016,13(3):80-82.
[16]刘晓燕,冯国和,吴立燕.无创正压通气治疗老年慢性阻塞性肺疾病合并重症Ⅱ型呼吸衰竭疗效分析及护理体会[J].浙江医学,2014,36(7):624-628.
[17]吕绍翔,霍敏琴.盐酸氨溴索支气管肺泡灌洗对慢性阻塞性肺疾病合并肺部感染的疗效[J].广东医学,2016,37(2):228-229.
[18]景璇,郭洁,张嘉,等.加味麻杏石甘汤配合穴位贴敷治疗老年慢性阻塞性肺病急性加重期患者的效果及对肺功能和肿瘤坏死因子-α、白细胞介素-8表达的影响[J].中国老年学杂志,2017,37(1):132-133.
[19]樊茂蓉,韩克华,王冰,等.通肺络补宗气方对特发性肺间质纤维化患者血清TGF-β、TNF-α、CTGF及PDGF的影响[J].辽宁中医杂志,2017,44(12):2572-2575.
[2]Mao T,Chen H,Hong L,et al. Pigment epithelium-derived factor inhibits high glucose-induced JAK/STAT signalling pathway activation in human glomerular mesangial cells[J]. Saudi Medical Journal,2013,12(34):3213-3215.
[3]李慧丽,焦凤梅,田昭涛,等.氧驱雾化吸入盐酸氨溴索治疗COPD急性加重期患者的临床疗效观察[J].湖南师范大学学报:医学版,2016,13(3):133-135.
[4]林金鱼,陈亚红.不同剂量盐酸氨溴索治疗慢性阻塞性肺疾病急性加重期老年患者的疗效比较[J].中国医药,2014,9(8):1120-1124.
[5]高静珍,陈宝元.盐酸氨溴索不同持续使用时间对慢性阻塞性肺疾病急性加重期的治疗效果[J].中华老年医学杂志,2014,33(3):294-296.
[6]陈锦平.盐酸氨溴索对慢性阻塞性肺疾病急性加重期肺功能及血清IL-10、TNF-α、CRP的影响[J].广西医学,2014,36(7):964-965,974.
[7]许斐,刘彦辉,刘晓芳.左西孟旦联合西地那非治疗慢性心力衰竭伴肺动脉高压的疗效观察[J].中西医结合心血管病电子杂志,2015,3(12):27,29.
[8]杨菊芳.分析麻杏石甘汤与银翘散联合加减治疗支气管肺炎患儿的临床疗效及安全性[J].中外医疗,2017,36(26):154-155,158.
[9]郭晓燕,徐向前,钱家骅,等.川芎平喘合剂对慢性阻塞性肺疾病肺动脉高压大鼠肺动脉平滑肌细胞增殖及对Rho激酶的影响[J].辽宁中医杂志,2017,44(12):2662-2664.
[10]董胜莲,汪凤兰,邢凤梅,等.自我效能系统干预对慢性阻塞性肺疾病患者生存质量的影响[J].现代预防医学,2014,41(18):3357-3359.
[11]郑灵春.布地奈德联合盐酸氨溴索雾化吸入治疗COPD急性加重期患者的疗效观察[J].医药前沿,2017,7(23):44-45.
[12]张丹凤,罗彩凤.赋能呼吸康复训练对慢性阻塞性肺疾病患者自我效能的影响[J].广东医学,2014,35(24):3932-3933.
[13]曹利花.舒适护理对老年慢性阻塞性肺疾病患者临床症状治疗依从性及生活自理能力的影响[J].中国药物与临床,2017,17(5):770-772.
[14]徐洪建.盐酸氨溴索联合α-糜蛋白酶雾化吸入治疗COPD急性加重期患者的疗效[J].中国处方药,2016,14(5):59-60.
[15]冼少静,石湘淋,黄奕江.慢性阻塞性肺疾病伴呼吸衰竭患者两种通气模式应用比较研究[J].湖南师范大学学报:医学版,2016,13(3):80-82.
[16]刘晓燕,冯国和,吴立燕.无创正压通气治疗老年慢性阻塞性肺疾病合并重症Ⅱ型呼吸衰竭疗效分析及护理体会[J].浙江医学,2014,36(7):624-628.
[17]吕绍翔,霍敏琴.盐酸氨溴索支气管肺泡灌洗对慢性阻塞性肺疾病合并肺部感染的疗效[J].广东医学,2016,37(2):228-229.
[18]景璇,郭洁,张嘉,等.加味麻杏石甘汤配合穴位贴敷治疗老年慢性阻塞性肺病急性加重期患者的效果及对肺功能和肿瘤坏死因子-α、白细胞介素-8表达的影响[J].中国老年学杂志,2017,37(1):132-133.
[19]樊茂蓉,韩克华,王冰,等.通肺络补宗气方对特发性肺间质纤维化患者血清TGF-β、TNF-α、CTGF及PDGF的影响[J].辽宁中医杂志,2017,44(12):2572-2575.